Monte Rosa Therapeutics (GLUE) News Today → Thousands of investors use this no cost solution | Do you? (From Insider Financial) (Ad) Free GLUE Stock Alerts $5.45 -0.02 (-0.37%) (As of 04/25/2024 ET) Add Compare Share Share HeadlinesStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestSocial Media All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative SourceHeadlineMonte Rosa Therapeutics, Inc. (NASDAQ:GLUE) Short Interest Updatemarketbeat.com - April 16 at 9:41 PMMonte Rosa Therapeutics (NASDAQ:GLUE) Shares Down 8.9% americanbankingnews.com - April 16 at 2:12 AMAnalysts Offer Insights on Healthcare Companies: Allogene Therapeutics (ALLO), Moderna (MRNA) and Monte Rosa Therapeutics (GLUE)markets.businessinsider.com - March 19 at 6:38 PMShort Interest in Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE) Decreases By 7.1%marketbeat.com - March 19 at 2:41 PMWall Street Analysts Predict an 117.91% Upside in Monte Rosa Therapeutics (GLUE): Here's What You Should Knowfinance.yahoo.com - March 19 at 1:37 PMMonte Rosa Therapeutics Inc (GLUE) Reports Full Year and Q4 2023 Financial Resultsfinance.yahoo.com - March 16 at 8:19 AMIs Monte Rosa Therapeutics (NASDAQ:GLUE) In A Good Position To Invest In Growth?finance.yahoo.com - March 15 at 10:57 AMPromising Clinical Progress and Strategic Milestones Bolster Buy Rating for Monte Rosa Therapeuticsmarkets.businessinsider.com - March 14 at 10:39 PMGLUE Stock Earnings: Monte Rosa Therapeutics Misses EPS for Q4 2023investorplace.com - March 14 at 3:03 PMMonte Rosa Therapeutics, Inc.: Monte Rosa Therapeutics Announces Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Updatefinanznachrichten.de - March 14 at 12:37 PMMonte Rosa Therapeutics: Q4 Earnings Insightsbenzinga.com - March 14 at 12:37 PMMonte Rosa Therapeutics Announces Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Updateglobenewswire.com - March 14 at 7:00 AMMonte Rosa Therapeutics Announces Initiation of IND Enabling Studies for MRT-8102, A First-in-Class NEK7 Directed Molecular Glue Degrader and NLRP3/IL-1β Pathway Inhibitorglobenewswire.com - March 11 at 7:00 AMFmr LLC Sells 540,899 Shares of Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE)marketbeat.com - March 4 at 5:02 AMMonte Rosa Therapeutics Inc GLUEmorningstar.com - March 1 at 4:31 PMMonte Rosa Therapeutics (GLUE) Price Target Increased by 5.66% to 16.32msn.com - February 24 at 10:01 PMMonte Rosa Therapeutics Stock (NASDAQ:GLUE), Analyst Ratings, Price Targets, Predictionsbenzinga.com - February 23 at 10:58 AMMonte Rosa draws bullish view at Wedbush on protein degradationmsn.com - February 15 at 6:25 PMMonte Rosa Therapeutics' AI And Machine Learning Platform Is Adding Significant Value Creation in Cancer Research: Analystmsn.com - February 15 at 6:25 PMMonte Rosa Therapeutics (NASDAQ:GLUE) Coverage Initiated by Analysts at Wedbushmarketbeat.com - February 15 at 7:24 AMMonte Rosa Therapeutics (NASDAQ:GLUE) Trading Down 4.3%marketbeat.com - February 13 at 3:03 AM3 Incredible Growth Stocks That Could Soar in 2024, According to Wall Streetfool.com - January 16 at 9:10 AMMonte Rosa Therapeutics Provides Corporate Update and Key Anticipated Milestones for 2024finance.yahoo.com - January 8 at 8:55 AMMonte Rosa Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conferencefinance.yahoo.com - January 3 at 8:18 AMMonte Rosa Therapeutics, Inc. (NASDAQ:GLUE) Sees Significant Decline in Short Interestmarketbeat.com - December 31 at 7:15 PMMonte Rosa Therapeutics Stock (NASDAQ:GLUE) Earnings Dates and Earning Callsbenzinga.com - December 4 at 8:46 PMMonte Rosa Therapeutics Stock (NASDAQ:GLUE) Dividends: History, Yield and Datesbenzinga.com - December 4 at 8:46 PMMonte Rosa Therapeutics to Present at Piper Sandler Healthcare Conferencefinance.yahoo.com - November 21 at 9:12 AMAnalysts’ Opinions Are Mixed on These Healthcare Stocks: Celldex (CLDX), Monte Rosa Therapeutics (GLUE) and Solid Biosciences (SLDB)markets.businessinsider.com - November 14 at 4:14 PMAnalysts Offer Insights on Healthcare Companies: Vertex (VERX) and Monte Rosa Therapeutics (GLUE)markets.businessinsider.com - November 10 at 9:31 AMMonte Rosa Therapeutics: Q3 Earnings Insightsbenzinga.com - November 9 at 2:12 PMMonte Rosa Therapeutics Announces Third Quarter 2023 Financial Results and Provides Corporate Updatefinance.yahoo.com - November 9 at 9:11 AMMonte Rosa Therapeutics Inc (GLUE) Reports Q3 2023 Financial Results and Strategic Developmentsfinance.yahoo.com - November 9 at 9:11 AMMonte Rosa Therapeutics Presents Preclinical Data at ACR Convergence 2023 Demonstrating Potential of MRT-6160, a VAV1-targeted Molecular Glue Degrader, to Treat Immunological and Inflammatory Diseasesfinance.yahoo.com - November 7 at 12:31 PMMonte Rosa Therapeutics, Inc. Common Stock (GLUE)nasdaq.com - October 31 at 3:12 PMMonte Rosa Therapeutics: Roche Partnership Deal Could Bring Added Valuemsn.com - October 31 at 10:12 AMMonte Rosa Therapeutics Shares Rise for Second Session in a Rowmarketwatch.com - October 30 at 10:47 PMMonte Rosa Therapeutics prices offering to raise $25Mmsn.com - October 26 at 6:24 PMMonte Rosa Therapeutics Announces $25 Million Registered Direct Offering, Priced At- the-Market Under Nasdaq Rulesfinance.yahoo.com - October 26 at 6:24 PMDown -56.34% in 4 Weeks, Here's Why You Should You Buy the Dip in Monte Rosa Therapeutics (GLUE)finance.yahoo.com - October 24 at 10:53 AMJP Morgan Maintains Monte Rosa Therapeutics (GLUE) Overweight Recommendationmsn.com - October 20 at 6:50 PMRoche signs $2.5B deal with Boston's Monte Rosa Therapeuticsbizjournals.com - October 17 at 11:07 PMRoche in pact with Monte Rosa to develop cancer and neuro drugsmsn.com - October 17 at 1:06 PMMonte Rosa Therapeutics Inks Strategic Collaboration With Roche To Develop Molecular Glue Degradersmarkets.businessinsider.com - October 17 at 1:06 PMMonte Rosa Therapeutics Announces Interim PK/PD and Clinical Data for MRT-2359 in Phase 1/2 Trial for MYC-Driven Solid Tumorsfinance.yahoo.com - October 17 at 8:06 AMMonte Rosa Therapeutics Announces Strategic Collaboration with Roche to Discover Novel Molecular Glue Degraders Targeting Cancer and Neurological Diseasesfinance.yahoo.com - October 17 at 8:06 AMGLUE - Monte Rosa Therapeutics, Inc.finance.yahoo.com - September 16 at 8:57 AM375,095 Shares in Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE) Acquired by Baker BROS. Advisors LPmarketbeat.com - September 12 at 5:41 AMMonte Rosa Therapeutics, Inc. (NASDAQ:GLUE) Holdings Lifted by Fmr LLCmarketbeat.com - September 7 at 5:13 AMFmr LLC Buys 203,581 Shares of Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE)marketbeat.com - September 7 at 5:13 AM Get Monte Rosa Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for GLUE and its competitors with MarketBeat's FREE daily newsletter. Email Address Red Alert: Your Money's Disappearance Act - Banks' Greed Unleashed! (Ad)Get your free information kit NOW, before it’s too late. Inside you’ll get the 3 secret strategies you can put in place starting today, so “they” don’t get your money tomorrow. Click here for your free guide GLUE Media Mentions By Week GLUE Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. GLUE News Sentiment▼0.000.41▲Average Medical News Sentiment GLUE News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. GLUE Articles This Week▼11▲GLUE Articles Average Week Get Monte Rosa Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for GLUE and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: MGX News IVVD News SOPH News BDTX News FENC News AVXL News TCRX News MGTX News TNYA News AURA News Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:GLUE) was last updated on 4/25/2024 by MarketBeat.com Staff From Our PartnersThe Best AI Stock to Own in the World Today is Trading for Just $25Banyan Hill PublishingConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial MetalsThese AI trades triggered this morning (545% return)Prosper Trading AcademyThe A.I. story nobody is telling you (Read ASAP)TradeSmithHe Is Giving Away BitcoinCrypto Swap ProfitsFed launches fourth dollar overhaulStansberry ResearchThe only accurate crypto trading system I know …Weiss RatingsBitcoin Rockets To Record High But Buy THIS InsteadParadigm Press Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Monte Rosa Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
